Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004
The global Phase IIb UC trial is a multi-center, randomized, double-blind, placebo-controlled clinical study which will recruit 210 patients with active mild-to-moderate UC. The patients will be randomized into one of the two HMPL-004 treatment arms, 1200mg/daily or 1800mg/daily, or the placebo arm. The primary endpoint of the trial is to assess the efficacy of HMPL-004 as compared with the placebo after eight weeks treatment. In the trial the efficacy of HMPL-004 will be assessed based on quantitative symptom reduction thresholds using the standard Mayo score as well as a rectal bleeding score derived from a colonoscopic examination. Secondary endpoints of the trial involve the clinical remission, mucosal healing, and the dose response trend of the two HMPL-004 treatment arms. Safety evaluations will be made throughout the trial period. It is anticipated that patient recruitment in this global clinical trial will be completed by third quarter 2009.
HMPL-004, the leading candidate of Chi-Med's drug pipeline for treating inflammatory bowel disease, is also being assessed as a potential treatment for Crohn's Disease ("CD"). The product candidate is in a Phase II clinical trial in the US which is actively recruiting patients and Chi-Med anticipates the completion of patient recruitment for this CD study by the end of 2008.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.